Enlivex Therapeutics
ENLV
ENLV
17 hedge funds and large institutions have $630K invested in Enlivex Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
3
Closed
2
Calls
$52K
Puts
–
Net Calls
+$52K
Net Calls Change
+$12K
Top Buyers
1 |
Morgan Stanley
New York
|
+$121K |
2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$75.4K |
3 |
Citigroup
New York
|
+$12.8K |
4 |
Renaissance Technologies
New York
|
+$8.66K |
5 |
UBS Group
Zurich,
Switzerland
|
+$8.03K |